<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:9f2feb57-030e-492a-aafa-39e4f6b005ba,g:6cacbeb8-d9fe-4cfd-8491-29e2afff14d1,d:d0d48aa78db9441b93e694272b10a1e9--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>tcda-20210106</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV80L2ZyYWc6ZTNhOWFmZmZkZDE2NDUwMWIyZTM2MTQ3NTEzMjZmZjYvdGFibGU6NzZkZjU1MWE1Yjg4NGJiN2E3YzE5ZGY4M2IzZjdiNTQvdGFibGVyYW5nZTo3NmRmNTUxYTViODg0YmI3YTdjMTlkZjgzYjNmN2I1NF8yLTEtMS0xLTA_08b1e9ff-708e-4343-b145-1fa4ded65c17">false</ix:nonNumeric><ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV80L2ZyYWc6ZTNhOWFmZmZkZDE2NDUwMWIyZTM2MTQ3NTEzMjZmZjYvdGFibGU6NzZkZjU1MWE1Yjg4NGJiN2E3YzE5ZGY4M2IzZjdiNTQvdGFibGVyYW5nZTo3NmRmNTUxYTViODg0YmI3YTdjMTlkZjgzYjNmN2I1NF8zLTEtMS0xLTA_8f975c23-8a67-4ca8-b720-0d18262ae67b">0001595585</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="tcda-20210106.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595585</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-06</xbrli:startDate><xbrli:endDate>2021-01-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id0d48aa78db9441b93e694272b10a1e9_1"></div><div style="min-height:43pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:139%"> UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:139%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:19pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:19pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGV4dHJlZ2lvbjo4Njk3ZDhmZjg1YWE0YjM4OTMwZWIzYTNkOTYyZDZkMl8zOTYx_5692bf21-46f3-4c73-b40a-81da1300eb97">8-K</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:139%">CURRENT REPORT</span></div><div style="margin-bottom:10pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-bottom:19pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGV4dHJlZ2lvbjo4Njk3ZDhmZjg1YWE0YjM4OTMwZWIzYTNkOTYyZDZkMl8yMjM_b25aa222-62b9-4a49-8244-925c3e9bd879">January 6, 2021</ix:nonNumeric></span></div><div style="margin-bottom:19pt;text-align:center"><img src="tcda-20210106_g1.jpg" alt="tcda-20210106_g1.jpg" style="height:58px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGV4dHJlZ2lvbjo4Njk3ZDhmZjg1YWE0YjM4OTMwZWIzYTNkOTYyZDZkMl8zOTY1_4349f541-3965-42a8-be79-1b7b559e7684">TRICIDA, INC.</ix:nonNumeric></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:35.703%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.612%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGFibGU6ZWFmMGJiODM3NjE3NGI2OWI3Y2JkMGVlYjFlNWQ2MjMvdGFibGVyYW5nZTplYWYwYmI4Mzc2MTc0YjY5YjdjYmQwZWViMWU1ZDYyM18wLTAtMS0xLTA_4cf0fa65-65fc-48e7-bea6-aee163f793cf">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGFibGU6ZWFmMGJiODM3NjE3NGI2OWI3Y2JkMGVlYjFlNWQ2MjMvdGFibGVyYW5nZTplYWYwYmI4Mzc2MTc0YjY5YjdjYmQwZWViMWU1ZDYyM18wLTItMS0xLTA_b72ffadd-9723-40b3-aa62-8a04c2ab34eb">001-38558</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGFibGU6ZWFmMGJiODM3NjE3NGI2OWI3Y2JkMGVlYjFlNWQ2MjMvdGFibGVyYW5nZTplYWYwYmI4Mzc2MTc0YjY5YjdjYmQwZWViMWU1ZDYyM18wLTQtMS0xLTA_44f3c8cd-b038-4525-a038-972f885d0bed">46-3372526</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%"><ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGV4dHJlZ2lvbjo4Njk3ZDhmZjg1YWE0YjM4OTMwZWIzYTNkOTYyZDZkMl8zOTU2_561b38f0-6cb3-484d-a727-dd48ac595362">7000 Shoreline Court</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%"><ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGV4dHJlZ2lvbjo4Njk3ZDhmZjg1YWE0YjM4OTMwZWIzYTNkOTYyZDZkMl8zOTY2_20cc365c-09ce-4635-9ded-98ccbb510d0e">Suite 201</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%"><ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGV4dHJlZ2lvbjo4Njk3ZDhmZjg1YWE0YjM4OTMwZWIzYTNkOTYyZDZkMl8zOTU4_42175451-aa37-419b-b3b2-81c6d86db3bd">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGV4dHJlZ2lvbjo4Njk3ZDhmZjg1YWE0YjM4OTMwZWIzYTNkOTYyZDZkMl8zOTYz_199ca0d5-8c0d-4760-8ce0-bdb92112a89d">CA</ix:nonNumeric> <ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGV4dHJlZ2lvbjo4Njk3ZDhmZjg1YWE0YjM4OTMwZWIzYTNkOTYyZDZkMl8zOTU5_e9b0cbd2-32e2-415b-89dd-a8e4f728fbd7">94080</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:139%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">(<ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGV4dHJlZ2lvbjo4Njk3ZDhmZjg1YWE0YjM4OTMwZWIzYTNkOTYyZDZkMl8zOTY0_a0d4ed2e-09f6-4d7d-9fa7-7e896824ce37">415</ix:nonNumeric>) <ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGV4dHJlZ2lvbjo4Njk3ZDhmZjg1YWE0YjM4OTMwZWIzYTNkOTYyZDZkMl8zOTYw_fa17b2a5-bd21-4b7b-bcd7-5852e3bf7a60">429-7800</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:139%">(Registrant&#8217;s telephone number, including area code</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.648%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:4.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGFibGU6ZDhmNjI1NDVhYzBhNDc1YmI1OWE3ZWMyN2JkZGU3MzYvdGFibGVyYW5nZTpkOGY2MjU0NWFjMGE0NzViYjU5YTdlYzI3YmRkZTczNl8wLTAtMS0xLTA_e93bb2f8-1ab4-43ed-97e5-1a4d86285896">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGFibGU6ZDhmNjI1NDVhYzBhNDc1YmI1OWE3ZWMyN2JkZGU3MzYvdGFibGVyYW5nZTpkOGY2MjU0NWFjMGE0NzViYjU5YTdlYzI3YmRkZTczNl8xLTAtMS0xLTA_d7365883-50d5-4381-a7be-553cca1a6e33">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGFibGU6ZDhmNjI1NDVhYzBhNDc1YmI1OWE3ZWMyN2JkZGU3MzYvdGFibGVyYW5nZTpkOGY2MjU0NWFjMGE0NzViYjU5YTdlYzI3YmRkZTczNl8yLTAtMS0xLTA_d363f235-d4d4-4ada-a412-fc8c0b331ea7">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGFibGU6ZDhmNjI1NDVhYzBhNDc1YmI1OWE3ZWMyN2JkZGU3MzYvdGFibGVyYW5nZTpkOGY2MjU0NWFjMGE0NzViYjU5YTdlYzI3YmRkZTczNl8zLTAtMS0xLTA_2c09a495-5abb-414d-8d62-b46cf178c8e8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:37.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.144%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGFibGU6YTM4MzIyZGQyNWNhNDY4ZGEyNDkxMjFjNGM5OGVmY2EvdGFibGVyYW5nZTphMzgzMjJkZDI1Y2E0NjhkYTI0OTEyMWM0Yzk4ZWZjYV8yLTAtMS0xLTA_a7cefe45-5532-42ad-b543-1f45cff4ab09">Common stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGFibGU6YTM4MzIyZGQyNWNhNDY4ZGEyNDkxMjFjNGM5OGVmY2EvdGFibGVyYW5nZTphMzgzMjJkZDI1Y2E0NjhkYTI0OTEyMWM0Yzk4ZWZjYV8yLTEtMS0xLTA_109cb096-cc30-4a75-8b48-cf64b8fa5004">TCDA</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGFibGU6YTM4MzIyZGQyNWNhNDY4ZGEyNDkxMjFjNGM5OGVmY2EvdGFibGVyYW5nZTphMzgzMjJkZDI1Y2E0NjhkYTI0OTEyMWM0Yzk4ZWZjYV8yLTItMS0xLTA_0766a06e-1f2f-462c-9aed-31f51717c8a3">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.265%"><tr><td style="width:1.0%"></td><td style="width:22.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:62.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.366%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf3af0ac846a4effa2d28909edaa11e0_D20210106-20210106" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmQwZDQ4YWE3OGRiOTQ0MWI5M2U2OTQyNzJiMTBhMWU5L3NlYzpkMGQ0OGFhNzhkYjk0NDFiOTNlNjk0MjcyYjEwYTFlOV8xL2ZyYWc6ODY5N2Q4ZmY4NWFhNGIzODkzMGViM2EzZDk2MmQ2ZDIvdGFibGU6MTEzYTU0YzIzMTAwNDllZGI1Zjk3NGQzZjQ3MzljODEvdGFibGVyYW5nZToxMTNhNTRjMjMxMDA0OWVkYjVmOTc0ZDNmNDczOWM4MV8wLTEtMS0xLTA_b0abfb6c-87a9-49b6-8475-9b7ed1099863">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr></table></div><div><span><br/></span></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:43pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.971%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Entry into a Material Definitive Agreement</span></div></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On January 6, 2021, Tricida, Inc. (the &#8220;Company&#8221;), as borrower, Hercules Capital, Inc., as administrative agent (in such capacity, the &#8220;Agent&#8221;), and each of the financial institutions party thereto as lenders (the &#8220;Lenders&#8221;) entered into the Sixth Amendment to Loan and Security Agreement (&#8220;Sixth Amendment&#8221;) to amend certain terms of the Loan and Security Agreement, dated as of February 28, 2018 (as amended by that certain First Amendment to Loan and Security Agreement and First Amendment to Warrants dated as of April 10, 2018, that certain Second Amendment to Loan and Security Agreement, dated as of October 15, 2018, that certain Third Amendment to Loan and Security Agreement, dated as of March 27, 2019, that certain Fourth Amendment to Loan and Security Agreement, dated as of March 31, 2020, that certain Fifth Amendment to Loan and Security Agreement, dated as of May 18, 2020 and the Sixth Amendment, the &#8220;Loan Agreement&#8221;, and the term loans thereunder, the &#8220;Term Loan&#8221;) by and among the Company, the Agent and the Lenders. The Sixth Amendment provides for, among other things, a decrease in the amount available under the Loan Agreement from $200.0 million to $75.0 million. The loan repayment schedule provides for interest only payments until April 1, 2022 (the &#8220;Amortization Date&#8221;), followed by consecutive equal monthly amortization payments of principal and interest through the maturity date. The maturity date of the Loan Agreement is October 1, 2023, subject to extension to April 1, 2024 on the condition that the Company obtains final approval from the U.S. Food and Drug Administration ("FDA") for the New Drug Application (&#8220;NDA&#8221;) for veverimer (also known as TRC101) (such final approval, the &#8220;TRC101 Approval&#8221;) on or before October 1, 2023. The Sixth Amendment also eliminates the 1.0% prepayment charge for prepayments of principal of the Term Loan made after March 1, 2021.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Sixth Amendment modifies certain covenants applicable to the Company under the Loan Agreement. Under the terms of the Sixth Amendment, the Company is required to at all times maintain unrestricted cash in an amount not less than 100% of the outstanding principal amount of the Term Loan, until the achievement of statistically significant positive data from the completion of either of the two interim analyses for efficacy (to be performed when approximately 150 and 250 subjects have had a positively adjudicated primary endpoint event) as described in Borrower&#8217;s Clinical Study Protocol TRCA-303 (VALOR-CKD) for veverimer, Amendment 2, dated November 18, 2020, of the ongoing VALOR-CKD trial, which, along with an acceptable safety profile, would support re-filing of the NDA for veverimer with the FDA, subject to verification by the Agent. From and after achievement of such positive data, the Company is required to at all times maintain unrestricted cash in an amount equal to 75% of the outstanding principal amount of the Term Loan until achievement of the TRC101 Approval, whereupon such unrestricted cash maintenance covenants shall cease to apply.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Sixth Amendment reduces, from $500.0 million to $300.0 million, the minimum market capitalization of the Company that triggers a covenant of the Company to deliver to the Agent monthly financial statements and related reporting.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The foregoing description of the Sixth Amendment and the Loan Agreement does not purport to be complete and is qualified in its entirety by reference, as applicable, to the full text of the Amendment, including exhibits attached thereto, a copy of which is attached hereto as Exhibit 10.1, in each case to this Current Report on Form 8-K, which is incorporated herein by reference.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.971%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;2.03</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</span></div></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The information set forth in Item 1.01 of this Current Report on Form 8-K with respect to the Amendment is incorporated by reference into this Item 2.03.</span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.971%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements and Exhibits.</span></td></tr></table></div><div style="margin-top:3pt;text-indent:18pt"><span><br/></span></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:43pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d) Exhibits.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.385%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101_hercules6tham.htm">Sixth Amendment to Loan and Security Agreement, dated as of January 6, 2021 among Tricida, Inc., Hercules Capital Inc. and the several banks and other financial institutions or entities from time to time parties thereto.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="id0d48aa78db9441b93e694272b10a1e9_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SIGNATURE</span></div><div style="margin-top:12pt;text-indent:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-indent:24pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.107%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: January 11, 2021</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRICIDA, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="6" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Geoffrey M. Parker</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geoffrey M. Parker</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer and Executive Vice President</span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "tcda-20210106.htm", "description": "8-K", "secsgml_size_bytes": 42612}]
{"company-data": {"conformed-name": "Tricida, Inc.", "cik": "0001595585", "assigned-sic": "2834", "irs-number": "463372526", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-38558", "film-number": "21519515"}, "business-address": {"street1": "7000 SHORELINE COURT, SUITE 201", "city": "SOUTH SAN FRANCISCO", "state": "CA", "zip": "94080", "phone": "415-429-7800"}, "mail-address": {"street1": "7000 SHORELINE COURT, SUITE 201", "city": "SOUTH SAN FRANCISCO", "state": "CA", "zip": "94080"}}
tcda-20210106
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 6, 2021
TRICIDA, INC.
(Exact name of Registrant as specified in its charter)
Delaware
001-38558
46-3372526
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification Number)
7000 Shoreline Court
Suite 201
South San Francisco
,
CA
94080
(Address of principal executive offices) (Zip Code)
(
415
)
429-7800
(Registrant's telephone number, including area code
)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act
Title of each class
Trading Symbol(s)
Name of exchange on which registered
Common stock, par value $0.001 per share
TCDA
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 1.01
Entry into a Material Definitive Agreement
On January 6, 2021, Tricida, Inc. (the "Company"), as borrower, Hercules Capital, Inc., as administrative agent (in such capacity, the "Agent"), and each of the financial institutions party thereto as lenders (the "Lenders") entered into the Sixth Amendment to Loan and Security Agreement ("Sixth Amendment") to amend certain terms of the Loan and Security Agreement, dated as of February 28, 2018 (as amended by that certain First Amendment to Loan and Security Agreement and First Amendment to Warrants dated as of April 10, 2018, that certain Second Amendment to Loan and Security Agreement, dated as of October 15, 2018, that certain Third Amendment to Loan and Security Agreement, dated as of March 27, 2019, that certain Fourth Amendment to Loan and Security Agreement, dated as of March 31, 2020, that certain Fifth Amendment to Loan and Security Agreement, dated as of May 18, 2020 and the Sixth Amendment, the "Loan Agreement", and the term loans thereunder, the "Term Loan") by and among the Company, the Agent and the Lenders. The Sixth Amendment provides for, among other things, a decrease in the amount available under the Loan Agreement from $200.0 million to $75.0 million. The loan repayment schedule provides for interest only payments until April 1, 2022 (the "Amortization Date"), followed by consecutive equal monthly amortization payments of principal and interest through the maturity date. The maturity date of the Loan Agreement is October 1, 2023, subject to extension to April 1, 2024 on the condition that the Company obtains final approval from the U.S. Food and Drug Administration ("FDA") for the New Drug Application ("NDA") for veverimer (also known as TRC101) (such final approval, the "TRC101 Approval") on or before October 1, 2023. The Sixth Amendment also eliminates the 1.0% prepayment charge for prepayments of principal of the Term Loan made after March 1, 2021.
The Sixth Amendment modifies certain covenants applicable to the Company under the Loan Agreement. Under the terms of the Sixth Amendment, the Company is required to at all times maintain unrestricted cash in an amount not less than 100% of the outstanding principal amount of the Term Loan, until the achievement of statistically significant positive data from the completion of either of the two interim analyses for efficacy (to be performed when approximately 150 and 250 subjects have had a positively adjudicated primary endpoint event) as described in Borrower's Clinical Study Protocol TRCA-303 (VALOR-CKD) for veverimer, Amendment 2, dated November 18, 2020, of the ongoing VALOR-CKD trial, which, along with an acceptable safety profile, would support re-filing of the NDA for veverimer with the FDA, subject to verification by the Agent. From and after achievement of such positive data, the Company is required to at all times maintain unrestricted cash in an amount equal to 75% of the outstanding principal amount of the Term Loan until achievement of the TRC101 Approval, whereupon such unrestricted cash maintenance covenants shall cease to apply.
The Sixth Amendment reduces, from $500.0 million to $300.0 million, the minimum market capitalization of the Company that triggers a covenant of the Company to deliver to the Agent monthly financial statements and related reporting.
The foregoing description of the Sixth Amendment and the Loan Agreement does not purport to be complete and is qualified in its entirety by reference, as applicable, to the full text of the Amendment, including exhibits attached thereto, a copy of which is attached hereto as Exhibit 10.1, in each case to this Current Report on Form 8-K, which is incorporated herein by reference.
Item 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The information set forth in Item 1.01 of this Current Report on Form 8-K with respect to the Amendment is incorporated by reference into this Item 2.03.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
10.1
Sixth Amendment to Loan and Security Agreement, dated as of January 6, 2021 among Tricida, Inc., Hercules Capital Inc. and the several banks and other financial institutions or entities from time to time parties thereto.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: January 11, 2021
TRICIDA, INC.
By:
/s/ Geoffrey M. Parker
Name:
Geoffrey M. Parker
Title:
Chief Financial Officer and Executive Vice President